Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    TRISENOX

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    QTX-2101 Receives FDA Fast Track For Acute Promyelocytic Leukemia
    QTX-2101 Receives FDA Fast Track For Acute Promyelocytic Leukemia

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228847/0/en/QTX-2101-Awarded-FDA-Fast-Track-Designation-for-the-Treatment-of-Acute-Promyelocytic-Leukemia.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Quetzal Therapeutics Launches Phase 3 Trial of QTX-2101 in APL
    Quetzal Therapeutics Launches Phase 3 Trial of QTX-2101 in APL

    02 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/02/3198337/0/en/Quetzal-Therapeutics-Launches-Phase-III-Clinical-Trial-of-Oral-QTX-2101-for-Acute-Promyelocytic-Leukemia-APL.html

    GLOBENEWSWIRE
    02 Dec 2025
    Share Share
    BioSenic Analyzes Phase 2 Data For Arsenic Trioxide In CGVHD Trial
    BioSenic Analyzes Phase 2 Data For Arsenic Trioxide In CGVHD Trial

    18 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/18/2915008/0/en/BioSenic-releases-new-in-depth-analysis-of-its-positive-phase-2-clinical-data-for-optimal-administration-scheme-for-its-next-late-stage-trial-of-arsenic-trioxide-ATO-targeting-cGvH.html

    GLOBENEWSWIRE
    18 Jul 2024
    Share Share
    Medsenic, subsidiary of BioSenic SA, extends key patent to the United States
    Medsenic, subsidiary of BioSenic SA, extends key patent to the United States

    05 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/05/2908872/0/en/Medsenic-subsidiary-of-BioSenic-SA-extends-key-patent-to-the-United-States.html

    GLOBENEWSWIRE
    05 Jul 2024
    Share Share
    Medsenic Signs New Licensing Agreements With Phebra PTY Ltd
    Medsenic Signs New Licensing Agreements With Phebra PTY Ltd

    02 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/02/2907129/0/en/Medsenic-BioSenic-s-subsidiary-signed-a-new-set-of-licensing-and-commercialization-agreements-with-Phebra-PTY-Ltd.html

    GLOBENEWSWIRE
    02 Jul 2024
    Share Share
    Medsenic amends licence agreement with Phebra for arsenic trioxide
    Medsenic amends licence agreement with Phebra for arsenic trioxide

    30 May 2023

    // PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/medsenic-licence-phebra-oato/

    PHARMACEUTICAL TECHNOLOGY
    30 May 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.